ICC (95% CI) for BML Scores | ||||
---|---|---|---|---|
Exercise 1 | ||||
(OAI) N=80 | (OAI) N=40 | Exercise 2 (Adalimumab) N=16 Between experts | ||
Between experts | N1 vs expert | N2 vs expert | ||
KIMRISS | ||||
Status | 0.84 (0.66 to 0.91) | 0.89 (0.79 to 0.94) | 0.98 (0.96 to 0.99) | 0.97 (0.90 to 0.99) |
Change | 0.82 (0.73 to 0.88) | 0.87 (0.77 to 0.93) | 0.92 (0.85 to 0.96) | 0.90 (0.73 to 0.96) |
MOAKS | ||||
Status | 0.79 (0.69 to 0.86) | 0.81 (0.67 to 0.90) | 0.87 (0.77 to 0.93) | 0.67 (0.25 to 0.87) |
Change | 0.53 (0.35 to 0.68) | 0.32 (0.01 to 0.57) | 0.51 (0.23 to 0.70) | 0.32 (−0.18 to 0.69) |
Reliability: novice readers versus expert readers (40 randomly selected patients from the 80 patient Exercise 1 cohort).
BML, bone marrow lesions; ICC, Intraclass Correlation Coefficients; KIMRISS, Knee Inflammation MRI Scoring System; MOAKS, MRI Osteoarthritis Knee Score; OAI, Osteoarthritis Initiative.